References
- Kyle RA, Gertz MA. Primary systemic amyloidosis. Clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45–59.
- Matsuda M, Gono T, Shimojima Y, Yoshida T, Katoh N, Hoshii Y, Yamada T, Ikeda S. AL amyloidosis manifesting as systemic lymphadenopathy. Amyloid: J Protein Folding Disord 2008;15:117–124.
- Skinner M, Sanchorawala V, Seldin DC, Dember LM, Falk RH, Berk JL, Anderson JJ, O'Hara C, Finn KT, Libbey CA, High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann Intern Med 2004;140:85–93.
- Biewend ML, Menke DM, Calamia KT. The spectrum of localized amyloidosis: a case series of 20 patients and review of the literature. Amyloid: J Protein Folding Disord 2006;13:135–142.
- Westermark P, Benson M, Buxbaum JN, Cohen AS, Frangione B, Ikeda S, Masters CL, Merlini G, Saraiva MJ, Sipe JD. A primer of amyloid nomenclature. Amyloid: J Protein Folding Disord 2007;14:179–183.
- Matsuda M, Gono T, Shimojima Y, Hoshii Y, Ikeda S. Phenotypic analysis of plasma cells in bone marrow using flow cytometry in AL amyloidosis. Amyloid: J Protein Folding Disord 2003;10:110–116.
- Matsuda M, Yamada T, Gono T, Shimojima Y, Ishii W, Fushimi T, Sakashita K, Koike K, Ikeda S. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis. Intern Med 2005;44:428–433.
- Gono T, Matsuda M, Shimojima Y, Ishii W, Koyama J, Sakashita K, Koike K, Hoshii Y, Ikeda S. VAD with or without subsequent high-dose melphalan followed by autologous stem cell support in AL amyloidosis: Japanese experience and criteria for patient selection. Amyloid: J Protein Folding Disord 2004;11:245–256.
- Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant 2007;40:557–562.
- Sachorawala V, Seldin DC. An overview of high-dose melphalan and stem cell transplantation in the treatment of AL amyloidosis. Amyloid: J Protein Folding Disord 2007;14:261–269.
- van Buren M, Hene RJ, Verdonck LF, Verzijbergen FJ, Lokhorst HM. Clinical remission after syngeneic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med 1995;122:508–510.
- van Gameren II, Hazenberg BPC, Jager PL, Smit JW, Vellenga E. AL amyloidosis treated with induction chemotherapy with VAD followed by high dose melphalan and autologous stem cell transplantation. Amyloid: J Protein Folding Disord 2002;9:165–174.
- Tazawa K, Katoh N, Shimojima Y, Matsuda M, Ikeda S. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with primary systemic AL amyloidosis. Amyloid: J Protein Folding Disord 2009;16:183–185.
- Hamidi K, Liepnieks JJ, Nakamura M, Benson MD. Organ-specific (localized) synthesis of Ig light chain amyloid. J Immunol 1999;162:5556–5560.
- Shimojima Y, Takei Y, Tazawa K, Gono T, Fushimi T, Matsuda M, Hoshii Y, Ikeda S. Histopathological regression of systemic AA amyloidosis after surgical treatment of a localized Castleman's disease. Amyloid: J Protein Folding Disord 2006;13:184–186.